$VTAK
Catheter Precision, Inc.

2021 Q4 Form 10-K Financial Statement

#000156459022011555 Filed on March 24, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $5.000K $22.00K $0.00
YoY Change -99.5% -100.0%
Cost Of Revenue $347.0K $1.560M $426.0K
YoY Change -18.54% -71.54% -75.66%
Gross Profit -$342.0K -$1.538M -$426.0K
YoY Change -19.72% 42.8% 18.33%
Gross Profit Margin -6840.0% -6990.91%
Selling, General & Admin $4.190M $15.48M $6.379M
YoY Change -34.32% -40.42% -26.19%
% of Gross Profit
Research & Development $3.732M $12.25M $3.421M
YoY Change 9.09% 36.02% 308.23%
% of Gross Profit
Depreciation & Amortization $315.0K $1.000M $520.0K
YoY Change -39.42% -37.5% 39.04%
% of Gross Profit
Operating Expenses $7.922M $27.73M $9.800M
YoY Change -19.16% -20.74% 3.38%
Operating Profit -$8.264M -$29.27M -$10.23M
YoY Change -19.19% -18.84% 3.92%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$19.00K $2.009M -$9.000K
YoY Change 111.11% 2182.95%
Pretax Income -$8.283M -$27.26M -$10.24M
YoY Change -19.07% -22.81% 5.13%
Income Tax $4.000K $4.000K $7.000K
% Of Pretax Income
Net Earnings -$8.287M -$25.07M -$10.44M
YoY Change -20.65% -30.45% 7.19%
Net Earnings / Revenue -165740.0% -113954.55%
Basic Earnings Per Share -$248.20
Diluted Earnings Per Share -$1.226M -$4.959M -$3.599M
COMMON SHARES
Basic Shares Outstanding 101.0K
Diluted Shares Outstanding 101.0K

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.05M $15.05M $23.91M
YoY Change -37.07% -37.07% -21.82%
Cash & Equivalents $15.05M $15.05M $23.91M
Short-Term Investments $0.00
Other Short-Term Assets $1.037M $1.037M $1.258M
YoY Change -17.57% -63.14% -32.37%
Inventory $986.0K $986.0K $877.0K
Prepaid Expenses
Receivables $21.00K $21.00K $24.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $17.09M $17.09M $27.62M
YoY Change -38.13% -38.13% -23.28%
LONG-TERM ASSETS
Property, Plant & Equipment $1.809M $3.919M $2.527M
YoY Change -28.41% -21.79% -49.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $36.00K $36.00K $45.00K
YoY Change -20.0% -95.54% -77.04%
Total Long-Term Assets $3.955M $3.955M $5.818M
YoY Change -32.02% -32.02% -28.0%
TOTAL ASSETS
Total Short-Term Assets $17.09M $17.09M $27.62M
Total Long-Term Assets $3.955M $3.955M $5.818M
Total Assets $21.04M $21.04M $33.44M
YoY Change -37.07% -37.07% -24.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $988.0K $988.0K $471.0K
YoY Change 109.77% 109.77% -69.26%
Accrued Expenses $4.119M $4.402M $4.147M
YoY Change -0.68% -2.24% 56.96%
Deferred Revenue $1.801M
YoY Change -11.24%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $686.0K
YoY Change -100.0% -100.0% 134.13%
Total Short-Term Liabilities $5.390M $5.390M $7.762M
YoY Change -30.56% -30.56% 13.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $1.579M
YoY Change -100.0% -100.0% 495.85%
Other Long-Term Liabilities $1.981M $1.981M $2.950M
YoY Change -32.85% -32.85% -23.42%
Total Long-Term Liabilities $1.981M $1.981M $4.529M
YoY Change -56.26% -56.26% 10.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.390M $5.390M $7.762M
Total Long-Term Liabilities $1.981M $1.981M $4.529M
Total Liabilities $7.371M $7.371M $12.29M
YoY Change -40.03% -40.03% 12.44%
SHAREHOLDERS EQUITY
Retained Earnings -$178.3M -$153.2M
YoY Change 16.36% 30.77%
Common Stock $191.9M $174.3M
YoY Change 10.09% 16.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.67M $13.67M $21.15M
YoY Change
Total Liabilities & Shareholders Equity $21.04M $21.04M $33.44M
YoY Change -37.07% -37.07% -24.14%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$8.287M -$25.07M -$10.44M
YoY Change -20.65% -30.45% 7.19%
Depreciation, Depletion And Amortization $315.0K $1.000M $520.0K
YoY Change -39.42% -37.5% 39.04%
Cash From Operating Activities -$5.711M -$27.60M -$9.414M
YoY Change -39.34% -2.49% -1.65%
INVESTING ACTIVITIES
Capital Expenditures -$41.00K $265.0K $5.000K
YoY Change -920.0% 295.52% -110.42%
Acquisitions
YoY Change
Other Investing Activities $40.00K $4.067M $0.00
YoY Change -74.58% -100.0%
Cash From Investing Activities -$1.000K $3.802M $5.000K
YoY Change -120.0% -76.14% -99.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $16.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 141.0K 14.96M -331.0K
YoY Change -142.6% -31.03% 7.47%
NET CHANGE
Cash From Operating Activities -5.711M -27.60M -9.414M
Cash From Investing Activities -1.000K 3.802M 5.000K
Cash From Financing Activities 141.0K 14.96M -331.0K
Net Change In Cash -5.571M -8.861M -9.740M
YoY Change -42.8% -195.05% -13627.78%
FREE CASH FLOW
Cash From Operating Activities -$5.711M -$27.60M -$9.414M
Capital Expenditures -$41.00K $265.0K $5.000K
Free Cash Flow -$5.670M -$27.87M -$9.419M
YoY Change -39.8% -1.78% -1.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
3473000
CY2021 us-gaap Description Of Defined Contribution Pension And Other Postretirement Plans
DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
All full-time employees are eligible to make voluntary contributions as a percentage or defined amount of compensation. The Company makes matching contributions based on 100% of each employee’s contribution up to 3% and 50% of contributions between 3% and 5%, with the match-eligible contribution limited to 4% of the employee’s eligible compensation.
CY2021 us-gaap Gross Profit
GrossProfit
-1538000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15475000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12253000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
88000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2237000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-26000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1560000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2009000
CY2020Q4 us-gaap Assets
Assets
33438000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
988000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
471000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4119000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4147000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
421000
CY2021 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
3473000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24000
CY2021Q4 us-gaap Inventory Net
InventoryNet
986000
CY2020Q4 us-gaap Inventory Net
InventoryNet
877000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1037000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1100000
CY2020Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
1713000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
17089000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
27620000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1809000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2527000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2110000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2484000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
36000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
45000
CY2020Q4 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
762000
CY2021Q4 us-gaap Assets
Assets
21044000
CY2020Q4 rmed Equipment Financing Obligations Current
EquipmentFinancingObligationsCurrent
265000
CY2020Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
2102000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5390000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7762000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
1579000
CY2020Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
686000
CY2020Q4 us-gaap Liabilities
Liabilities
12291000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
174342000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-153202000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2023000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000
CY2021 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-5.39
CY2020 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-20.79
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.43
CY2020 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
-0.43
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.96
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-21.22
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5055000
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1699000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-25070000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-36045000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-26000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25070000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36071000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
33150000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11625000
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
7492000
CY2020 rmed Exercise Of Warrants
ExerciseOfWarrants
827000
CY2020 rmed Common Stock Issued Pursuant To The Vesting Of Restricted Stock Units And Employee Stock Purchase Plan
CommonStockIssuedPursuantToTheVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlan
42000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4082000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-36045000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
21147000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15153000
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
132000
CY2021 rmed Common Stock Issued Pursuant To The Vesting Of Restricted Stock Units And Employee Stock Purchase Plan
CommonStockIssuedPursuantToTheVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlan
74000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-25070000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
13673000
CY2021 us-gaap Profit Loss
ProfitLoss
-25070000
CY2020 us-gaap Profit Loss
ProfitLoss
-36045000
CY2021 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
3473000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2023000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2237000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
4082000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1565000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2365000
CY2021 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
550000
CY2020 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-99000
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
47000
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
180000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-42000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-368000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
197000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-352000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-150000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-642000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
627000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-961000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-390000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1706000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-234000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-774000
CY2021 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-356000
CY2020 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-318000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27625000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28304000
CY2021 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
3700000
CY2021 rmed Payment Of Fees Related To Sale Of Discontinued Operations
PaymentOfFeesRelatedToSaleOfDiscontinuedOperations
227000
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
594000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
265000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67000
CY2020 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
16000000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3802000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15933000
CY2021 rmed Proceeds From Issuance Of Common Stock And Warrants Net Of Placement Agent Fees
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfPlacementAgentFees
15528000
CY2020 rmed Proceeds From Issuance Of Common Stock And Warrants Net Of Placement Agent Fees
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfPlacementAgentFees
19887000
CY2021 rmed Payments Of Offering Costs Related To Issuance Of Common Stock And Warrants
PaymentsOfOfferingCostsRelatedToIssuanceOfCommonStockAndWarrants
375000
CY2020 rmed Payments Of Offering Costs Related To Issuance Of Common Stock And Warrants
PaymentsOfOfferingCostsRelatedToIssuanceOfCommonStockAndWarrants
770000
CY2021 rmed Repayment Of Equipment Financing
RepaymentOfEquipmentFinancing
265000
CY2020 rmed Repayment Of Equipment Financing
RepaymentOfEquipmentFinancing
293000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
74000
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
42000
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2000000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
827000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14962000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21693000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8861000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9322000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23906000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14584000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15045000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23906000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
17000
CY2020 rmed Transfer From Inventories To Property And Equipment For Demonstration Lasers Lasers And Lasers Placed With Customers
TransferFromInventoriesToPropertyAndEquipmentForDemonstrationLasersLasersAndLasersPlacedWithCustomers
207000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
2000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
28000
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
2000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-178300000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27600000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15000000.0
CY2021 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior period amounts have been reclassified to conform to the current period presentation as further described in Note 3. <span style="font-style:italic;">Discontinued Operations</span>.</p>
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <span style="color:#000000;">financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The</span> preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. The Company’s financial statements are based upon a number of estimates including, but not limited to, allowance for credit losses, evaluation of impairment of assets, valuation of long-lived assets and their associated estimated useful lives, reserves for warranty costs, including product recalls, evaluation of probable loss contingencies and fair value of equity awards granted. </p>
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 us-gaap Disposal Group Including Discontinued Operation Costs Of Goods Sold
DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
3311000
CY2019Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
234000
CY2021 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
9000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
84000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
305000
CY2021 rmed Provision For Credit Losses Continuing Operations
ProvisionForCreditLossesContinuingOperations
47000
CY2020 rmed Provision For Credit Losses Continuing Operations
ProvisionForCreditLossesContinuingOperations
42000
CY2020 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
263000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
131000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
84000
CY2020 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
4146000
CY2021 us-gaap Disposal Group Including Discontinued Operation Costs Of Goods Sold
DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
2290000
CY2020 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
53000
CY2020 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
19000
CY2020 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
4000
CY2021Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
195000
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
204000
CY2021 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credit risk represents the accounting loss that would be recognized at the reporting date if counterparties failed completely to perform as contracted. Concentrations of credit risk that arise from financial instruments exist for groups of customers or counterparties when they have similar economic characteristics that would cause their ability to meet contractual obligations to be similarly affected by changes in economic or other conditions described below. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist of cash equivalent balances maintained in excess of Federal Depository Insurance Corporation limits, and accounts receivable which have no collateral or security. The Company monitors the financial condition of the banks in which it currently has deposits. The Company has not experienced any significant losses in this respect and believes that it is not exposed to any significant related risk. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exposure to losses on accounts receivable is dependent upon the individual customer’s financial condition. The Company monitors its exposure to credit losses and reserves for those accounts receivable that it deems to be not collectible. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2021 and 2020, we had three and four individual customers, respectively, that represented greater than 10% of total net revenues. One individual customer represented greater than 10% of accounts receivable at each of December 31, 2021 and 2020.</p>
CY2021 rmed Capitalized Contract Cost Amortization Period1
CapitalizedContractCostAmortizationPeriod1
P1Y
CY2020Q4 us-gaap Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net
DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
214000
CY2020Q4 us-gaap Disposal Group Including Discontinued Operation Inventory Current
DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
1341000
CY2020Q4 us-gaap Disposal Group Including Discontinued Operation Prepaid And Other Assets Current
DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
158000
CY2020Q4 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment Current
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
684000
CY2020Q4 us-gaap Disposal Group Including Discontinued Operation Other Assets
DisposalGroupIncludingDiscontinuedOperationOtherAssets
78000
CY2020Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
2475000
CY2020Q4 us-gaap Disposal Group Including Discontinued Operation Accounts Payable Current
DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
100000
CY2020Q4 us-gaap Disposal Group Including Discontinued Operation Accrued Liabilities
DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities
201000
CY2020Q4 us-gaap Disposal Group Including Discontinued Operation Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationDeferredRevenue
2487000
CY2020Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
2788000
CY2021 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
2600000
CY2021 rmed Gros Income Loss From Discontinued Operations
GrosIncomeLossFromDiscontinuedOperations
310000
CY2020 rmed Gros Income Loss From Discontinued Operations
GrosIncomeLossFromDiscontinuedOperations
835000
CY2021 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
1498000
CY2020 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
1494000
CY2021 rmed Disposal Group Including Discontinued Operation Operating Income Loss Gross
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLossGross
-1188000
CY2020 rmed Disposal Group Including Discontinued Operation Operating Income Loss Gross
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLossGross
-659000
CY2021 rmed Disposal Group Including Discontinued Operation Interest Income Expense Net
DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpenseNet
-94000
CY2020 rmed Disposal Group Including Discontinued Operation Interest Income Expense Net
DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpenseNet
-66000
CY2021 us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
-1282000
CY2020 us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
-725000
CY2021 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
3473000
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
2191000
CY2020 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-725000
CY2021 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
0
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
911000
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
547000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
70000
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
270000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
60000
CY2021Q4 us-gaap Inventory Net
InventoryNet
986000
CY2020Q4 us-gaap Inventory Net
InventoryNet
877000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
507000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4119000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4147000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
472000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
486000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
501000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2795000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4658000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5653000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2849000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3126000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1809000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2527000
CY2021 us-gaap Depreciation
Depreciation
1000000.0
CY2020 us-gaap Depreciation
Depreciation
1600000
CY2021 us-gaap General Discussion Of Pension And Other Postretirement Benefits
GeneralDiscussionOfPensionAndOtherPostretirementBenefits
In January 2019, the Company established a defined contribution plan under Section 401(k) of the Internal Revenue Code (“401(k) Plan”). Under the terms of the 401(k) Plan, all full-time employees are eligible to make voluntary contributions as a percentage or defined amount of compensation. The Company makes matching contributions based on 100% of each employee’s contribution up to 3% and 50% of contributions between 3% and 5%, with the match-eligible contribution limited to 4% of the employee’s eligible compensation.
CY2019 us-gaap Defined Contribution Plan Administrative Expenses
DefinedContributionPlanAdministrativeExpenses
300000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2004000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2479000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1345000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
957000
CY2021Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
195000
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
204000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
575000
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
204000
CY2021 rmed Operating Lease Number Of Leases
OperatingLeaseNumberOfLeases
2
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y
CY2021Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.07
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
500000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
500000
CY2021 rmed Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
400000
CY2020 rmed Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
400000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
432000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
445000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
459000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
531000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2264000
CY2020Q2 rmed Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
73506
CY2021Q4 rmed Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
556000
CY2020Q4 rmed Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
691000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
71000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
101000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
399000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
448000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
169000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
299000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
642000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
15562000
CY2020 us-gaap Defined Contribution Plan Administrative Expenses
DefinedContributionPlanAdministrativeExpenses
300000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2054000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3682000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
56000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
32000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4605000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4910000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.013
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.051
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.026
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.022
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Exempt Income
EffectiveIncomeTaxRateReconciliationTaxExemptIncome
0.017
CY2020 rmed Effective Income Tax Rate Reconciliation Deferred Tax Adjustments
EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustments
0.570
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.001
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.214
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.332
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
4000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
7000
CY2021 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
4000
CY2020 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
7000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9706000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3720000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10843000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
348000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
805000
CY2021Q4 rmed Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
518000
CY2020Q4 rmed Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
655000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
61000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
866000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1521000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
14696000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9322000
CY2021 rmed Operating Loss Carryforwards Expiration Year
OperatingLossCarryforwardsExpirationYear
2030
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
20800000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021 rmed Income Tax Examination Years Under Examination
IncomeTaxExaminationYearsUnderExamination
2017 and later
CY2021 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
3811170
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16000000.0

Files In Submission

Name View Source Status
0001564590-22-011555-index-headers.html Edgar Link pending
0001564590-22-011555-index.html Edgar Link pending
0001564590-22-011555.txt Edgar Link pending
0001564590-22-011555-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gxdxvtfbvi0w000001.jpg Edgar Link pending
gxdxvtfbvi0w000002.jpg Edgar Link pending
gxdxvtfbvi0w000003.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rmed-10k_20211231.htm Edgar Link pending
rmed-10k_20211231_htm.xml Edgar Link completed
rmed-20211231.xsd Edgar Link pending
rmed-20211231_cal.xml Edgar Link unprocessable
rmed-20211231_def.xml Edgar Link unprocessable
rmed-20211231_lab.xml Edgar Link unprocessable
rmed-20211231_pre.xml Edgar Link unprocessable
rmed-ex231_507.htm Edgar Link pending
rmed-ex232_10.htm Edgar Link pending
rmed-ex311_7.htm Edgar Link pending
rmed-ex312_8.htm Edgar Link pending
rmed-ex321_9.htm Edgar Link pending
rmed-ex322_11.htm Edgar Link pending
rmed-ex42_6.htm Edgar Link pending
Show.js Edgar Link pending